ISOAPI-D™ - Deuterated Reagents for Pharmaceuticals



Cambridge Isotope Laboratories, Inc. (CIL) has long been the trusted partner for pharmaceutical innovators seeking stable isotope-labeled materials for advanced synthesis. Now, we’re proud to introduce ISOAPI-D™ — a new brand built specifically for the next generation of deuterated reagents in pharmaceutical development.


ISOAPI-D combines CIL’s decades of expertise and global manufacturing footprint with a diversified, secure supply chain, premium deuterated materials, and rigorous quality assurance. Whether you’re developing novel APIs or optimizing existing drug candidates, ISOAPI-D empowers your team with smarter, stronger therapeutic foundations. Our solutions deliver proven advantages — extended half-life, improved metabolic profiles, and more efficient production — backed by full traceability and compliance with the highest industry standards. Explore how ISOAPI-D can help you accelerate API innovation, minimize risk, and deliver new therapeutic possibilities with confidence.

In recent years, some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical benefits of new deuterated drugs is also occurring.

The potential advantages of deuterated pharmaceuticals include:

Deuterated Reagents for Pharmaceutical and Synthetic Applications

Download

Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.

Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track, allowing more of the unmetabolized drug to reach its target.

Increased half-life. Deuterated compounds can have a slower pharmacokinetic effect, extending the absorption and distribution in the body. This may decrease the number of doses a patient may require in certain time period compared to its nondeuterated counterpart.

Related Resources

➤ Stable Isotopes in Drug Development
 ➤ Basic Starting Materials and Synthetic Intermediates
➤ Deuterated Reagents and High-Purity Gases
➤ Isotopic Enrichment and Species Abundance

 Beyond the Hype: How a Single Neutron Is Revolutionizing Drug Metabolism and API Design


 Precision Engineering: The Synthesis, Scale-Up, and Quality Control of Deuterated APIs


 Beyond Purity: Characterizing the Isotopologue Profile of a Deuterated API


 From Bench to Blockbuster: The Definitive Clinical and Commercial Analysis of Deuterated Drugs


ISOAPI-D™ is a trademark of Cambridge Isotope Laboratories, Inc. (CIL).

Isotope Label

Label Type

Isotopic Enrichment Range

Grade

Molecular Weight Range

Product Form

Product Form 2

❛❛Cambridge Isotopes has been a partner to Concert for many years. Our relationship has been successful not only because of the quality of material supplied but the accompanying service and expertise they offer. Importantly, Cambridge Isotopes is a company that works with you, not for you.❜❜

Stuart Gebbie | Director, Pharmaceutical Development, Concert Pharmaceutical

Frequently Asked Questions

What do I do if I need multiple vials or carboys when returning D2O for the D2O Recovery Program? If you have more than ~16 L you may require multiple carboys, please just ask.

When returning D2O for the D2O Recovery Program should I fill the carboy to the top? No! Fill the bulk carboy container ~80% full. Most are shipped by FedEx Air, and if full, the carboy is likely to expand and possibly rupture the container.

Example References

Di Martino, R.M.C.; Maxwell, B.D.; Pirali, T. 2023. Deuterium in drug discovery: progress, opportunities and challenges. Nat Rev Drug Discov, 2(7), 562-584. PMID: 37277503
Mullard, A. 2022. First de novo deuterated drug poised for approval. Nat Rev Drug Discov, 21(9), 623-625. PMID: 35974147
Falb, E.; Ulanenko, K.; Tor, A.; et al. 2017. A highly efficient Suzuki-Miyaura methylation of pyridines leading to the drug pirfenidone and its CD3 version (SD-560). Green Chemistry, 21. Read article
Pepper Hamilton LLP. 2017. Deuterated drugs are new chemical entities. JDSUPRA® Read more
Mullard, A. 2016. Deuterated drugs draw heavier backing. Nat Rev Drug Discov, 15(4), 219-221. PMID: 27032821
2015. Drugs that live long will prosper. The Economist Science & Technology, Sept. 5 edition. economist.com. Read article
Tung, R. 2010. The development of deuterium-containing drugs. Innovations Pharm Technol, 32(32), 24-28. Read article